Application of metabonomics in drug development

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Nicholson JK, Lindon JC, Holmes E: ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica29(11),1181–1189 (1999).
  Medline CASGoogle Scholar
• 2  Fiehn O: Metabolomics – the link between genotypes and phenotypes. Plant Mol. Biol.48,155–171 (2002).
  Medline CASGoogle Scholar
• 3  Raamsdonk LM, Teusink B, Broadhurst D et al.: A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotech.19(1),45–50 (2001).
  Medline CASGoogle Scholar
• 4  Griffin JL, Williams HJ, Sang E, Clarke K, Rae C, Nicholson JK: Metabolic profiling of genetic disorders: a multitissue ¹H nuclear magnetic resonance spectroscopic and pattern recognition study into dystrophic tissue. Anal. Biochem.293(1),16–21 (2001).
  Medline CASGoogle Scholar
• 5  Robertson DG: Metabonomics in toxicology: a review. Toxicol. Sci.85(2),809–822 (2005).
  Medline CASGoogle Scholar
• 6  Keun HC: Metabonomic modeling of drug toxicity. Pharmacol. Ther.109(1–2),92–106 (2006).
  Medline CASGoogle Scholar
• 7  Brindle JT, Antti H, Holmes E et al.: Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using ¹H-NMR-based metabonomics. Nat. Med.8(12),1439–1444 (2003).
  Google Scholar
• 8  Forgue P, Halouska S, Werth M, Xu K, Harris S, Powers R: NMR metabolic profiling of Aspergillus nidulans to monitor drug and protein activity. J. Proteome Res.5(8),1916–1923 (2006).• Use of metabolic profiling in a drug-discovery mode, via a functional genomics-like strategy.
  Medline CASGoogle Scholar
• 9  Glunde K, Ackerstaff E, Mori N et al.: Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol. Pharmaceutics3(5),496–506 (2006).
  Medline CASGoogle Scholar
• 10  Glunde K, Serkova NJ: Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics7(7),1109–1123 (2006).
  CASGoogle Scholar
• 11  Griffin JL, Kauppinen RA: Tumour metabolomics in animal models of human cancer. J. Proteome Res.6(2),498–505 (2007).
  Medline CASGoogle Scholar
• 12  Glunde K, Ackerstaff E, Natarajan K, Artemov D, Bhujwall ZM: Real-time changes in ¹H and ³¹P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn. Reson. Med.48(5) 819–825 (2002).
  Medline CASGoogle Scholar
• 13  Adebodun F: Phospholipid metabolism and resistance to glucocorticoid-induced apoptosis in a human leukemic cell line: a ³¹P-NMR study using a phosphonium analog of choline. Cancer Lett.140(1–2),189–194 (1999).
  Medline CASGoogle Scholar
• 14  Al-Saffar NMS, Troy H, Ramírez de Molina A et al.: Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res.66(1),427–434 (2006).•• Exemplifies the successful translation of pharmacodynamic metabolic markers, and the development of drugs against a metabolic target.
  Medline CASGoogle Scholar
• 15  Espina JR, Shockcor JP, Herron WJ et al.: Detection of in vivo biomarkers of phospholipidosis using NMR-based metabonomic approaches. Magn. Reson. Chem.39(9),559–565 (2001).
  CASGoogle Scholar
• 16  Garrod S, Humpher E, Connor SC et al.: High-resolution ¹H NMR and magic angle spinning NMR spectroscopic investigation of the biochemical effects of 2-bromoethanamine in intact renal and hepatic tissue. Magn. Reson. Med.45(5),781–790 (2001).
  Medline CASGoogle Scholar
• 17  Holmes E, Bonner FW, Sweatman BC et al.: Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury(II) chloride and 2-bromoethanamine. Mol. Pharmacol.42(5),922–930 (1992).
  Medline CASGoogle Scholar
• 18  Beckwith-Hall BM, Nicholson JK, Nicholls AW et al.: Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem. Res. Toxicol.11(4),260–272 (1998).
  Medline CASGoogle Scholar
• 19  Lindon JC, Keun HC, Ebbels TMD et al.: The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics6(7),691–699 (2005).
  CASGoogle Scholar
• 20  Sinha G: Trying to catch troublemakers with a metabolic profile. Science310(5750),965–966 (2005).
  Medline CASGoogle Scholar
• 21  Dieterle F, Schlotterbeck G, Ross A, Niederhauser U, Senn H: Application of metabonomics in a compound ranking study in early drug development revealing drug-induced excretion of choline into urine. Chem. Res. Toxicol.19(9),1175–1181 (2006).• Shows how metabonomics can contribute to lead selection/optimization.
  Medline CASGoogle Scholar
• 22  Soga T, Baran R, Suematsu M et al.: Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem.281(24),16768–16776 (2006).•• An example of how noninvasive surrogate markers can be screened for and validated using a metabolic profiling approach.
  Medline CASGoogle Scholar
• 23  Clayton TA, Lindon JC, Cloarec O et al.: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature440(7087),1073–1077 (2006).•• First proof-of-principle experiment to show that pretreatment metabolic profiles can be predictive of response to drug exposure.
  Medline CASGoogle Scholar
• 24  Holmes E, Tsang TM, Huang JT et al.: Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med.3(8),1420–1428 (2006).• Evidence for metabolism revealing clinical subpopulations.
  CASGoogle Scholar
• 25  Dumas ME, Barton RH, Toye A et al.: Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl Acad. Sci. USA103(33),12511–12516 (2006).• Detailed example of interactions between genomes at the metabolic level.
  Medline CASGoogle Scholar
• 26  Stella C, Beckwith-Hall B, Cloarec O et al.: Susceptibility of human metabolic phenotypes to dietary modulation. J. Proteome Res.5(10),2780–2788 (2006).
  Medline CASGoogle Scholar
• 27  Robosky LC, Wells DF, Egnash LA et al.: Metabonomic identification of two distinct phenotypes in Sprague–Dawley (Crl:CD(SD)) rats. Toxicol. Sci.87(1),277–284 (2005).
  Medline CASGoogle Scholar
• 28  Nicholson JK, Wilson ID: Understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov.2(8),668–676 (2003).
  Medline CASGoogle Scholar
• 29  Plumb RS, Granger JH, Stumpf CL et al.: A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst130(6),884–849 (2005).
  MedlineGoogle Scholar
• 30  Ullsten S, Danielsson R, Bäckström D, Sjöberg P, Bergquist J: Urine profiling using capillary electrophoresis–mass spectrometry and multivariate data analysis. J. Chromatogr. A1117(1),87–93 (2006).
  Medline CASGoogle Scholar
• 31  Casado B, Zanone C, Annovazzi L, Iadarola P, Whalen G, Baraniuk JN: Urinary electrophoretic profiles from chronic fatigue syndrome and chronic fatigue syndrome/fibromyalgia patients: a pilot study for achieving their normalization. J. Chromatogr. B Analyst Technol. Biomed. Life Sci.814(1),43–51 (2005).
  Medline CASGoogle Scholar
• 32  Szymañska E, Markuszewski MJ, Capron X et al.: Increasing conclusiveness of metabonomic studies by cheminformatic preprocessing of capillary electrophoretic data on urinary nucleoside profiles. J. Pharm. Biomed. Anal.43(2),413–420 (2007).
  Medline CASGoogle Scholar
• 33  Ellis DI, Goodacre R: Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. Analyst131,875–885 (2006).
  Medline CASGoogle Scholar
• 34  Torgrip RJO, Lindberg J, Linder M et al.: New modes of data partitioning based on PARS peak alignment for improved multivariate biomarker/biopattern detection in ¹H-NMR spectroscopic metabolic profiling of urine. Metabolomics2(1),1–19 (2006).
  Medline CASGoogle Scholar
• 35  Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC: Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal. Chem.78(7) 2262–2267 (2006).
  Medline CASGoogle Scholar
• 36  Halouska S, Powers R: Negative impact of noise on the principal component analysis of NMR data. J. Magn. Reson.178(1) 88–95 (2006).
  Medline CASGoogle Scholar
• 37  Keun HC, Ebbels TMD, Antti H et al.: Improved analysis of multivariate data by variable stability scaling: application to NMR-based metabolic profiling. Anal. Chim. Acta490(1–2) 265–276 (2003).
  CASGoogle Scholar
• 38  Cloarec O, Dumas ME, Craig A et al.: Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic ¹H NMR data sets. Anal Chem.77(5),1282–1289 (2005).
  Medline CASGoogle Scholar
• 39  Crockford DJ, Holmes E, Lindon JC et al.: Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal. Chem.78(2),363–371 (2006).• Outlines a strategy for metabolite identification that directly integrates complementary analytical data.
  Medline CASGoogle Scholar
• 40  Pan Z, Gu H, Talaty N et al.: Principal component analysis of urine metabolites detected by NMR and DESI-MS in patients with inborn errors of metabolism. Anal. Bioanal. Chem.387,539–549 (2007).
  Medline CASGoogle Scholar
• 41  Rantalainen M, Cloarec O, Beckonert O et al.: Statistically integrated metabonomic–proteomic studies on a human prostate cancer xenograft model in mice. J. Proteome Res.5(10),2642–2655 (2006).
  Medline CASGoogle Scholar
• 42  Visapaa H, Bui M, Huang Y et al.: Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology61(4),845–850 (2003).
  MedlineGoogle Scholar
• 43  Thor AD, Edgerton SM, Liu S, Moore DH, Kwiatkowski DJ: Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin. Cancer Res.7(8),2415–2424 (2001).
  Medline CASGoogle Scholar
• 44  Shieh DB, Godleski J, Herndon JE et al.: Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer85(1) 47–57 (1999).
  Medline CASGoogle Scholar
• 45  Yang J, Tan D, Asch HL et al.: Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer46(1),29–42 (2004).
  MedlineGoogle Scholar
• 46  Craig A, Sidaway J, Holmes E et al.: Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. J. Proteome Res.5(7),1586–1601 (2006).
  Medline CASGoogle Scholar
• 47  Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol.19(3),1720–1730 (1999).
  Medline CASGoogle Scholar
• 48  Keun HC, Ebbels TMD, Antti H et al.: Analytical reproducibility in ¹H NMR-based metabonomic urinalysis. Chem. Res. Toxicol.15(11),1380–1386 (2002).
  Medline CASGoogle Scholar
• 49  Fell D: Understanding the Control of Metabolism. Portland Press Ltd, London, UK (1997).
  Google Scholar
• 50  Lindon JC, Nicholson JK, Holmes E et al.: Summary recommendations for standardization and reporting of metabolic analyses. Nat. Biotechnol.23(10),833–838 (2005).
  Medline CASGoogle Scholar